Escitalopram (Lexapro)

Safety Summary

Regulatory Status

Sources

These citations are the ones recorded for the human adult context.

• FDA Prescribing Information: Escitalopram (Lexapro) — MDD/GAD; Black Box suicidality; QT prolongation 20mg limit; minimal CYP interactions; pediatric MDD ≥12yr; 2012 QT safety communication; S-enantiomer of citalopram (2023) REGULATORY · 2023
• ASPCA Animal Poison Control Center: SSRI/SNRI Toxicosis in Dogs and Cats — serotonin syndrome; cyproheptadine treatment; toxic dose thresholds; fluoxetine/sertraline/paroxetine/escitalopram comparison; clinical signs and management (2023) VETERINARY · 2023
• LEXAPRO™ (escitalopram oxalate) TABLETS/ORAL SOLUTION REGULATORY
• CELEXA (citalopram) tablets, for oral use REGULATORY
• Lexapro® (escitalopram) tablets, for oral use REGULATORY
• TEDX List of Potential Endocrine Disruptors, full export (Excel from the publisher's own search, operator-saved 2026-10-08; list last updated September 2018) REFERENCE_DATABASE
• OEHHA Proposition 65 List of Carcinogens or Reproductive Toxicants (CSV, list date 31-Jul-26) REGULATORY
• Permissible Exposure Limits – OSHA Annotated Table Z-1 REGULATORY
• EPA CompTox CTX API: predicted properties for DTXSID8048440 (Escitalopram (Lexapro)) REFERENCE

Same data as the API response, which is open and needs no key. The full per-record source list is available to authenticated callers.